Navigation Links
Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Date:2/22/2011

WOBURN, Mass., Feb. 22, 2011 /PRNewswire/ -- MedTrust Online (MedTrust) and Avantra Biosciences (Avantra) announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx™ multiplex immunoassay system.

The two companies will provide a global community of over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.  Avantra, based in Woburn, MA, is a leading innovator in protein diagnostics and recently announced the commercialization of the new Q400 Biomarker Workstation and innovative AngioGenQx™ BioChip immunoassay.  The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring only five minutes for sample preparation.  

As Avantra's scientific development team identifies biomarkers of interest for its QPDx™ system, MedTrust will use its Knowledge Medicine™ platform to engage oncologists in online discussions that will validate the role of different panels in diagnosis, prognosis, and treatment efficacy in cancer care.  The first of several multiplex assays to be evaluated include an upcoming panel developed in the recently announced collaboration between Avantra and TGen Drug Development.  Avantra intends to develop additional panels that may target ovarian, pancreatic, lung, prostate, breast, and colorectal cancers to uncover associations between protein marker levels and patient drug responses that can positively impact clinical decisions.   Currently available for research use only (RUO), Avantra intends to seek regulatory approval for its assay technologies as the clinical utility of the molecular information becomes evident.   In addition to oncology, Avantra is exploring opportunities in other areas such as infectious disease through its upcoming panel for sepsis.

"Avantra is excited to work with MedTrust Online and their clinical experts on this joint collaboration.  Avantra's novel QPDx system is an easy-to-use multiplex protein biomarker technology that will provide MedTrust's user base with rapid, high utility, protein biomarker data.  Avantra is working on several key strategic initiatives to combine proteomic and genomic products and services technologies that will assist professionals in the research, clinical and pharmaceutical fields to make better decisions for drug profiling, patient stratification and disease management.  Our relationship with MedTrust Online is another key component to our strategy for building Avantra and our long term vision," said Brian McKernan, CEO of Avantra Biosciences.

"This partnership will provide cancer doctors with powerful biomarker assays that can be validated with clinical insights about their utility at the point of care," said Dr. Christopher Yoo, CEO of MedTrust.  "The result of this joint effort will be better decisions based on the most accurate molecular knowledge available about an individual patient's disease.  We believe Avantra's technology will bring a higher level of accuracy than what's currently available and MedTrust is delighted to work with Avantra on this important advancement in cancer care."

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site. For more information visit: www.avantrabio.com.

About MedTrust Online, LLC

MedTrust Online LLC, www.medtrust-online.com, headquartered in Scottsdale, Arizona, provides oncologists with clinically useful technology applications and solutions. MedTrust Online brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine to capture, organize, analyze, integrate and present the most up-to-date medical facts from a vast array of sources. This data is provided to doctors in a comprehensive yet concise way unavailable anywhere else.


'/>"/>
SOURCE Avantra Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):